Browse topics

Clinical guides / Glaucoma

Primary open-angle glaucoma

Updated

At a glance

Chronic optic neuropathy with an open angle. Diagnose from structure and function, not pressure alone.

CAVE [1][2]

  • An atypical field defect, disproportionate pallor or rapid visual loss suggests another diagnosis.

Clinical presentation [1][2]

  • Often asymptomatic.
  • Look for neuroretinal rim loss, RNFL defects and reproducible visual-field loss.

Diagnosis & investigations [1][2]

  • Establish untreated IOP where available, gonioscopy, central corneal thickness, disc/RNFL photography, OCT and reproducible automated fields. Inspect OCT segmentation and scan quality, especially in high myopia; the colour code is not a diagnosis.
  • Stage damage using reliable fields, including central testing when fixation is threatened. Compare both event and trend analyses; repeat a questionable change before calling progression unless immediate treatment is required.

Differential diagnosis [1][2]

  • Ocular hypertension, physiological cupping, myopic disc changes and nonglaucomatous optic neuropathy.

Treatment [1][2]

  • Set the initial target from baseline pressure, severity, age, life expectancy and fellow-eye status; revise it using the measured rate of progression. A pressure inside the population “normal range” may still be too high for this eye.
  • Choose the least burdensome strategy capable of protecting useful vision. Consider preservative-free preparations when surface toxicity limits adherence. Discuss benefits, daily workload and expected limits of laser or surgery.
Choose and adjust treatment [1][2]
FindingActionTiming / detail
New non-advanced open-angle glaucomaDiscuss 360° SLT or a topical prostaglandin analogue; set a measurable target and record baseline IOPSLT is a first-line option, not only a rescue after drops
Target not reachedCheck instillation, adherence, tolerability and IOP variation; add a different drug class, SLT or surgeryDo not duplicate mechanisms or escalate on one unreliable measurement
Advanced damage, fixation threatened or progression at the current targetLower the target and discuss filtering surgery promptly; do not rely on a slow sequence of marginal medication changesThe required pressure reduction may exceed what angle-based MIGS can provide
Drug selectionProstaglandins: ocular surface/hyperaemia and iris/periocular changes. Beta-blockers: asthma, bradycardia and AV block. Alpha-agonists: allergy, fatigue and important paediatric restrictionsCarbonic anhydrase inhibitors: review renal disease and product-specific contraindications; punctal occlusion reduces systemic exposure

Follow-up [1][2]

  • After starting or changing therapy, check effect and tolerability within weeks rather than waiting for the routine field visit. NICE reassessment ranges include 1–4 months for uncontrolled IOP without detected progression, and 1–2 months when progression and uncontrolled IOP coexist.
  • With controlled IOP and no progression, NICE suggests 6–12 months for high clinical risk and 12–18 months for low risk. Use shorter intervals for advanced disease, uncertain tests or rapid change; obtain enough early fields to estimate the slope.

Risk factors & context [1][2]

  • Age, family history and elevated IOP inform risk.
  • Glaucoma can also develop within the statistically normal pressure range.

Complications [1][2]

  • Irreversible field loss and impaired daily function.
  • Treatment intolerance or poor adherence can undermine pressure control.

When to refer [1][2]

  • Escalate for progression despite treatment, advanced damage or inability to reach the target.
References 2
  1. European Glaucoma Society · Terminology and Guidelines for Glaucoma ↗6th edition · 2025 · Clinical examination; classification; treatment principles
  2. NICE · Glaucoma: diagnosis and management ↗NG81 · updated 26 January 2022 · 1.2 Diagnosis; 1.4 Treatment; 1.5 Reassessment

European guidance. Drug availability and authorisations must be checked locally.

Evidence provenance

Evidence searched through
20 Sept 2026
Geographic applicability
European guidance. Drug availability and authorisations must be checked locally.
Version
fe291a631423
Guideline versions used
  • European Glaucoma Society · Terminology and Guidelines for Glaucoma · 6th edition · 2025
  • NICE · Glaucoma: diagnosis and management · NG81 · updated 26 January 2022
View references →